CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RemAb Therapeutics is developing RA-01, a novel drug aimed at preventing and treating infections in Intensive Care Units. This therapy targets specific antibodies to enhance patient protection without contributing to antibiotic resistance.
Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide.
Themost critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases atICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity.
This new drugallows an immediate pr…
REMAB THERAPEUTICS SL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
